A recent study by the ICMR National Centre for Disease Informatics and Research warns of a 5.6% annual increase in Indian breast cancer cases, driven by various risk factors.

Menopausal hormone therapy (MHT) does not raise breast cancer risk in women with breast cancer gene mutations, while estrogen only MHT leads to reduced risk.

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

SAN ANTONIO – Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results ...

Cedars Sinai gets 30M to establish a specialized BRCA cancer center focusing on research, diagnosis, and treatment in Los Angeles.

TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.

Angelina Jolie's long-rumored relocation plans are very much alive and gaining momentum, according to close sources.

FDA approved niraparib, abiraterone acetate, and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer, showing significant rPFS improvement in the AMPLITUDE trial. The ...

Angelina Jolie is reportedly preparing to leave Los Angeles behind as she plans a new life abroad focused on privacy, freedom ...

Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...